[
    [
        {
            "time": "",
            "original_text": "光大医药|19年报&20Q1点评】金域医学：疫情之下业绩仍实现增长，国家大基金背书未来可期",
            "features": {
                "keywords": [
                    "光大医药",
                    "金域医学",
                    "疫情",
                    "业绩增长",
                    "国家大基金"
                ],
                "sentiment_score": 0.75,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "光大医药|19年报&20Q1点评】金域医学：疫情之下业绩仍实现增长，国家大基金背书未来可期",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]